ImmuCell Corp Files Form 8-K

TL;DR

ImmuCell Corp just filed an 8-K on 3/4/24 - big deal incoming?

AI Summary

On March 4, 2024, ImmuCell Corporation entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Portland, Maine, filed this current report on Form 8-K.

Why It Matters

This filing indicates a significant event for ImmuCell Corporation, likely related to a new contract or business development that could impact its operations and financial standing.

Risk Assessment

Risk Level: medium — Form 8-K filings often signal material events, but the specific nature of the agreement is not detailed, requiring further investigation.

Key Numbers

• 001-12934 — SEC File Number (Identifies the company's filing with the SEC.)
• 01-0382980 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• ImmuCell Corporation (company) — Registrant
• March 4, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Portland, Maine (location) — Address of principal executive offices
• 207-878-2770 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC Nasdaq I

Filing Documents

• ea0201306-8k_immucell.htm (8-K) — 27KB
• ea0201306ex10-1_immucell.htm (EX-10.1) — 30KB
• 0001213900-24-020389.txt ( ) — 230KB
• iccc-20240304.xsd (EX-101.SCH) — 3KB
• iccc-20240304_lab.xml (EX-101.LAB) — 33KB
• iccc-20240304_pre.xml (EX-101.PRE) — 22KB
• ea0201306-8k_immucell_htm.xml (XML) — 3KB

01 Entry Into a Material Definitive Agreement

Item 1.01 Entry Into a Material Definitive Agreement. On March 4, 2024, ImmuCell Corporation (the "Company") entered into an Amending Agreement (the "Amendment") with Norbrook Laboratories Limited ("Norbrook"), which Amendment amends that certain Development Services and Commercial Supply Agreement, dated September 5, 2019, by and between the Company and Norbrook (as amended to date, the "Agreement"). Pursuant to the Agreement, Norbrook provides certain formulation, aseptic filling and packaging services for the Company at its FDA-licensed facility in connection with the regulatory approval and subsequent commercial product sales of Re-Tain , our purified Nisin treatment for subclinical mastitis in lactating dairy cows. The Amendment provides, among other things, that the Agreement between the Company and Norbrook shall terminate automatically on November 30, 2024 (subject to the terms of the Agreement). The forgoing description of the Amendment is qualified in its entirety by reference to the Amendment, which is filed as Exhibit 10.1 hereto and incorporated herein by this reference.

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amending Agreement between the Company and Norbrook Laboratories Limited dated as of March 4, 2024. 104 Cover Page Interactive Data File 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: March 6, 2024 By: /s/ Michael F. Brigham Michael F. Brigham President and Chief Executive Officer 2 EXHIBIT INDEX Exhibit No. Description 10.1 Amending Agreement between the Company and Norbrook Laboratories Limited dated as of March 4, 2024. 104 Cover Page Interactive Data File 3

View Full Filing

View this 8-K filing on SEC EDGAR